MarineMax Expands Role for EVP and Chief Digital Officer Shawn Berg
Mr. Berg joined MarineMax as Vice President of Technology in 2017 and was promoted to his current role in 2019. With more than 30 years of experience, he has held multiple officer-level positions, helping to drive growth for companies in the marine, automotive, and retail sectors. He possesses deep expertise in finance, insurance, distribution, service, and supply chain operations.
'Shawn's leadership, strategic perspective, and clear understanding of the industry make him well-suited for this expanded role,' stated Brett McGill, MarineMax's Chief Executive Officer and President. 'By giving Shawn the added responsibility for coordinating strategic growth initiatives across all of our global divisions, we are advancing the Company's commitment to delivering industry-leading customer experiences and sustainable financial performance."
MarineMax maintains a clear focus on innovation and customer-driven growth, utilizing technology, acquisitions, and service excellence to lead the recreational marine sector. Working with the other members of the Company's leadership team, Mr. Berg will contribute to refining and executing MarineMax's strategic roadmap, emphasizing operational excellence, market expansion, digital transformation and world-class customer service.
'I am honored to take on this expanded role to help advance MarineMax's long-term growth,' Mr. Berg said. 'I look forward to working with the team to deliver enhanced value to our customers, partners, and shareholders.'
About MarineMax
As the world's largest recreational boat and yacht retailer, marina operator and superyacht services company, MarineMax (NYSE: HZO) is United by Water. We have over 120 locations worldwide, including over 70 dealerships and 65 marina and storage facilities. Our integrated business includes IGY Marinas, which operates luxury marinas in yachting and sport fishing destinations around the world; Fraser Yachts Group and Northrop & Johnson, leading superyacht brokerage and luxury yacht services companies; Cruisers Yachts, one of the world's premier manufacturers of premium sport yachts, motor yachts, and Aviara luxury dayboats; and Intrepid Powerboats, a premier manufacturer of powerboats. To enhance and simplify the customer experience, we provide financing and insurance services as well as leading digital technology products that connect boaters to a network of preferred marinas, dealers, and marine professionals through Boatyard and Boatzon. In addition, we operate MarineMax Vacations in Tortola, British Virgin Islands, which offers our charter vacation guests the luxury boating adventures of a lifetime. Land comprises 29% of the earth's surface. We're focused on the other 71%. Learn more at www.marinemax.com.
Forward Looking Statement
Certain statements in this press release are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. These statements, including those related to the expansion of Shawn Berg's role to support the Company's growth and innovation initiatives, are based on current expectations, forecasts, risks, uncertainties, and assumptions that may cause actual results to differ materially from expectations as of the date of this release. These risks, assumptions, and uncertainties include the return to normal operations of the Company's locations, the timing of and potential outcome of the Company's long-term improvement plan, the estimated impact resulting from the Company's cost-reduction initiatives, the Company's abilities to reduce inventory, manage expenses and accomplish its goals and strategies, the quality of the new product offerings from the Company's manufacturing partners, the performance and integration of the recently acquired businesses, general economic conditions, as well as those within the Company's industry, the liquidity and strength of our bank group partners, the level of consumer spending, and numerous other factors identified in the Company's Form 10-K for the fiscal year ended September 30, 2024 and other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
Exonate plans ‘CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
CAMBRIDGE, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407. The CLEAR-DE (Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients with non-proliferative diabetic retinopathy (NPDR). The progression to a Phase IIb clinical study follows encouraging results from Exonate's Phase Ib/IIa study in March 2024. In the study, lead candidate EXN407 met its primary safety and tolerability endpoints, with no drug-related serious adverse events, and high patient compliance. Importantly, exploratory efficacy signals showed a reduction in vascular leakage, a key pathological driver in diabetic retinopathy. The Phase IIb trial to investigate the efficacy of EXN407 in NPDR patients is planned to begin in early 2026, with 140 patients currently enrolled across multiple sites in Australia, the Middle East and China. Diabetic retinopathy (DR) is a leading cause of vision loss globally. An estimated one-third of the nearly 500 million people living with diabetes are affected by NPDR, the early stage of diabetic eye disease, which can lead to more severe, vision-threatening complications. Current therapeutic approaches involve monthly intraocular injections, initiated only after symptoms appear. This limits opportunities for early therapeutic benefit, and due to the invasive nature and frequency, is often deferred until irreversible damage has occurred. EXN407 is a first-in-class, twice-daily topical formulation of a selective SRPK1 inhibitor – a minimally-invasive approach with potential to become the first effective eye-drop therapy for NPDR and diabetic macular oedema (DME). Designed to modulate expression of vascular endothelial growth factor (VEGF) via alternative mRNA splicing, EXN407 selectively inhibits the pro-angiogenic isoforms that drive disease progression, causing abnormal and leaky blood vessel formation in the retina. ' The Phase Ib/IIa data demonstrated the clear potential of EXN407 as a non-invasive treatment for diabetic eye disease, ' said Dr. Catherine Beech, Chief Executive Officer of Exonate. ' This therapy could transform the treatment landscape for early-stage disease by providing clinical benefit while avoiding the burden of injections, representing a significant advancement for patients and physicians alike. We're excited to progress to the CLEAR-DE Phase IIb trial and are actively seeking strategic partners to support its execution.' For more information about Exonate's pipeline and clinical development plans, please visit:
Business Wire
29 minutes ago
- Business Wire
Sea Limited to Report Second Quarter 2025 Results
SINGAPORE--(BUSINESS WIRE)--Sea Limited (NYSE: SE) ('Sea' or the 'Company') plans to announce its second quarter 2025 results before the U.S. market opens on August 12, 2025, U.S. Eastern Time. The Company's management will host a conference call to discuss the second quarter 2025 results. A live webcast of this conference call will be available on the Company's website. Details of the webcast are as follows: A replay of the conference call will be available at the Company's investor relations website ( An archived webcast will be available at the same link above. About Sea Sea Limited (NYSE: SE) is a leading global consumer internet company founded in Singapore in 2009. Its mission is to better the lives of consumers and small businesses with technology. Sea operates three core businesses across digital entertainment, e-commerce, as well as digital financial services, known as Garena, Shopee and Monee, respectively. Garena is a leading global online games developer and publisher. Shopee is the largest pan-regional e-commerce platform in Southeast Asia and Taiwan and has a significant presence in Latin America. Monee is a leading digital financial services provider in Southeast Asia and is growing its presence in Brazil. For more information, visit
Forbes
30 minutes ago
- Forbes
How Will Altria Stock React To Its Upcoming Earnings?
CHONGQING, CHINA - JULY 28: In this photo illustration, a person holds a smartphone displaying the ... More logo of Altria Group Inc. (NYSE: MO), one of the largest tobacco and nicotine product manufacturers in the United States, with a colorful mosaic background featuring the company's brand identity, on July 28, 2025 in Chongqing, China. (Photo illustration by) Altria (NYSE:MO) is set to announce its earnings on Wednesday, July 30, 2025. For traders focused on events, gaining insight into historical stock performance during earnings periods can offer a significant advantage, although the actual outcomes versus consensus estimates will primarily influence market reactions. In the past five years, Altria's stock has delivered a positive one-day return in 53% of the cases following earnings announcements. When the returns were positive, the median one-day increase was 1.9%, with the highest one-day increase reaching 7.8%. Two key strategies to consider include: Analysts project that Altria will report earnings of $1.38 per share on revenues of $5.19 billion. This is in comparison to the same quarter last year, during which Altria reported earnings of $1.31 per share on revenue of $5.28 billion. From a fundamental standpoint, Altria has a current market capitalization of $101 billion. In the past twelve months, the company generated $20 billion in revenue, with $12 billion in operating profits and a net income of $10 billion, indicating robust operational profitability. Nonetheless, if you are looking for growth with less volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative—it has outperformed the S&P 500 and produced returns greater than 91% since its launch. Also, check out – Time To Buy Centene Stock? See earnings reaction history of all stocks Altria's Historical Odds Of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding observed 5-Day (5D) and 21-Day (21D) returns following earnings is included along with the statistics in the table below. MO 1D, 5D, and 21D Post Earnings Return Correlation Between 1D, 5D, and 21D Historical Returns A relatively less risky approach (although it may not be beneficial if the correlation is weak) is to grasp the correlation between short-term and medium-term returns following earnings, identify the pair with the highest correlation, and execute the suitable trade. For instance, if 1D and 5D demonstrate the highest correlation, a trader can adopt a "long" position for the next 5 days if the 1D post-earnings return is favorable. Below is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns. MO Correlation Between 1D, 5D and 21D Historical Returns Is There Any Correlation With Peer Earnings? Occasionally, the performance of peers can impact post-earnings stock reactions. In fact, the pricing might start prior to the earnings announcement. Below is some historical data comparing the past post-earnings performance of Altria stock with the performance of peers that reported earnings just before Altria. For a fair comparison, peer stock returns also reflect post-earnings one-day (1D) returns. MO Correlation With Peer Earnings Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (combination of the S&P 500, S&P mid-cap, and Russell 2000), producing strong returns for its investors. Additionally, if you're looking for growth with a less turbulent experience than investing in a single stock like Altria, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.
